JP2013533228A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013533228A5 JP2013533228A5 JP2013513651A JP2013513651A JP2013533228A5 JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5 JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013513651 A JP2013513651 A JP 2013513651A JP 2013533228 A5 JP2013533228 A5 JP 2013533228A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- salt
- solvate
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 C*C([C@](C(C)C)NC([C@](C(C)C)NC)=O)=* Chemical compound C*C([C@](C(C)C)NC([C@](C(C)C)NC)=O)=* 0.000 description 15
- XELCRLBPFJTQMS-KDXRVNOWSA-N CC[C@H](C)[C@H](C)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC Chemical compound CC[C@H](C)[C@H](C)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC XELCRLBPFJTQMS-KDXRVNOWSA-N 0.000 description 2
- MWKDAYPCKCUCIO-QWRGUYRKSA-N CC(C)[C@@H](C(C)=O)NC([C@H](C(C)C)NC)=O Chemical compound CC(C)[C@@H](C(C)=O)NC([C@H](C(C)C)NC)=O MWKDAYPCKCUCIO-QWRGUYRKSA-N 0.000 description 1
- GKMGYJQBUYQYBE-BKIBZHPOSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OC(C2)C22C=CC12)=O)=O)OC)=O)OC)N(C)C([C@H](C)NC([C@H](C(C)C)NC)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OC(C2)C22C=CC12)=O)=O)OC)=O)OC)N(C)C([C@H](C)NC([C@H](C(C)C)NC)=O)=O GKMGYJQBUYQYBE-BKIBZHPOSA-N 0.000 description 1
- NKLNWUSRAQEWFE-UFINBUOZSA-N CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OCc2ccccc2C1)=O)=O)OC)=O)OC)/C=C(\C)/CC([C@H](C(C)C)NC([C@H](C(C)=C)NC)=O)=O Chemical compound CC[C@H](C)[C@@H]([C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OCc2ccccc2C1)=O)=O)OC)=O)OC)/C=C(\C)/CC([C@H](C(C)C)NC([C@H](C(C)=C)NC)=O)=O NKLNWUSRAQEWFE-UFINBUOZSA-N 0.000 description 1
- PRGSRHOCNFFQKN-PRNUUREKSA-N CC[C@H](C)[C@H](CC(C)CC([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](Cc1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC Chemical compound CC[C@H](C)[C@H](CC(C)CC([C@H](C(C)C)NC([C@H](C(C)C)NC)=O)=O)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@H](Cc1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC PRGSRHOCNFFQKN-PRNUUREKSA-N 0.000 description 1
- UHSZKRYFCPMXMW-SFXSRNHCSA-N CC[C@H](C)[C@H](CCC(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCC(O)=O)=O)=O)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC Chemical compound CC[C@H](C)[C@H](CCC(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCC(O)=O)=O)=O)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(N[C@@H](Cc1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC UHSZKRYFCPMXMW-SFXSRNHCSA-N 0.000 description 1
- IJKQWIOKVAMDPA-VQYQWNPTSA-N CC[C@H](C)[C@H](CCC(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCN)=O)=O)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(CCC[C@@](C1)([C@H]1c1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC Chemical compound CC[C@H](C)[C@H](CCC(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)CCCN)=O)=O)[C@@H](CC(N(CCC1)[C@@H]1[C@@H]([C@@H](C)C(CCC[C@@](C1)([C@H]1c1ccccc1)C(N1OCCCC1)=O)=O)OC)=O)OC IJKQWIOKVAMDPA-VQYQWNPTSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10165550.4 | 2010-06-10 | ||
| EP10165550 | 2010-06-10 | ||
| EP11158464 | 2011-03-16 | ||
| EP11158464.5 | 2011-03-16 | ||
| PCT/EP2011/059300 WO2011154359A1 (de) | 2010-06-10 | 2011-06-06 | Neue auristatin-derivate und ihre verwendung |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013533228A JP2013533228A (ja) | 2013-08-22 |
| JP2013533228A5 true JP2013533228A5 (https=) | 2014-07-03 |
| JP5791707B2 JP5791707B2 (ja) | 2015-10-07 |
Family
ID=44275637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013513651A Active JP5791707B2 (ja) | 2010-06-10 | 2011-06-06 | 新規アウリスタチン誘導体およびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8722629B2 (https=) |
| EP (1) | EP2579887B1 (https=) |
| JP (1) | JP5791707B2 (https=) |
| CN (1) | CN103200950B (https=) |
| CA (1) | CA2801971C (https=) |
| ES (1) | ES2528956T3 (https=) |
| WO (1) | WO2011154359A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8987209B2 (en) | 2010-09-29 | 2015-03-24 | Seattle Genetics, Inc. | N-carboxyalkyl-auristatin and the use thereof |
| US9029406B2 (en) | 2011-03-16 | 2015-05-12 | Seattle Genetics, Inc | N-carboxyalkylauristatins and use thereof |
| KR102023496B1 (ko) * | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
| MY168297A (en) | 2011-11-17 | 2018-10-23 | Pfizer | Cytotoxic Peptides and Antibody Drug Conjugates Thereof |
| AU2012351685A1 (en) * | 2011-12-14 | 2014-07-03 | Seattle Genetics, Inc. | FGFR antibody drug conjugates (ADCs) and the use thereof |
| US10226535B2 (en) | 2012-12-10 | 2019-03-12 | Mersana Therapeutics, Inc. | Auristatin compounds and conjugates thereof |
| PL2968440T3 (pl) | 2013-03-15 | 2019-12-31 | Zymeworks Inc. | Związki cytotoksyczne i antymitotyczne oraz sposoby ich stosowania |
| FR3005051A1 (fr) * | 2013-04-25 | 2014-10-31 | Pf Medicament | Derives de la dolastatine 10 et d'auristatines |
| RU2729194C2 (ru) | 2013-12-27 | 2020-08-05 | Займворкс Инк. | Сульфонамидсодержащие связывающие системы для лекарственных конъюгатов |
| AU2014373640B2 (en) | 2013-12-27 | 2018-08-30 | Var2 Pharmaceuticals Aps | VAR2CSA-drug conjugates |
| BR112016024363A2 (pt) | 2014-04-25 | 2017-10-10 | Pf Medicament | conjugado de anticorpo-fármaco e seu uso para tratamento de câncer |
| RU2692563C2 (ru) | 2014-04-25 | 2019-06-25 | Пьер Фабр Медикамент | Конъюгат антитела против igf-1r с лекарственным средством и его применение для лечения рака |
| AU2015318556C1 (en) * | 2014-09-17 | 2021-01-07 | Zymeworks Bc Inc. | Cytotoxic and anti-mitotic compounds, and methods of using the same |
| CN106279352B (zh) | 2015-05-29 | 2020-05-22 | 上海新理念生物医药科技有限公司 | 海兔毒素10的衍生物及其应用 |
| WO2017161206A1 (en) | 2016-03-16 | 2017-09-21 | Halozyme, Inc. | Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use |
| US10517958B2 (en) | 2016-10-04 | 2019-12-31 | Zymeworks Inc. | Compositions and methods for the treatment of platinum-drug resistant cancer |
| CN108690119B (zh) * | 2018-06-04 | 2022-04-19 | 莎穆(上海)生物科技有限公司 | 一种伊文思蓝修饰的多肽类前药及其制备和应用 |
| JP7717832B2 (ja) | 2021-04-10 | 2025-08-04 | ジェンマブ エー／エス | Ｆｏｌｒ１結合剤、そのコンジュゲートおよびこれを使用する方法 |
| WO2022226317A1 (en) | 2021-04-23 | 2022-10-27 | Profoundbio Us Co. | Anti-cd70 antibodies, conjugates thereof and methods of using the same |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| MX2024002571A (es) | 2021-09-03 | 2024-03-20 | Toray Industries | Composicion farmaceutica para tratamiento y/o prevencion de cancer. |
| AU2024353316A1 (en) | 2023-09-26 | 2026-03-26 | Genmab A/S | Ptk7 binding agents, conjugates thereof and methods of using the same |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5663149A (en) * | 1994-12-13 | 1997-09-02 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides |
| WO1999035164A1 (en) * | 1998-01-09 | 1999-07-15 | Arizona Board Of Regents, A Body Corporate, Acting On Behalf Of Arizona State University | Anti-cryptococcal peptides |
| CA2370245A1 (en) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Enzyme-activated anti-tumor prodrug compounds |
| US6323315B1 (en) | 1999-09-10 | 2001-11-27 | Basf Aktiengesellschaft | Dolastatin peptides |
| US6884869B2 (en) | 2001-04-30 | 2005-04-26 | Seattle Genetics, Inc. | Pentapeptide compounds and uses related thereto |
| US6737409B2 (en) | 2001-07-19 | 2004-05-18 | Hoffmann-La Roche Inc. | Dolastatin 10 derivatives |
| WO2003026577A2 (en) | 2001-09-24 | 2003-04-03 | Seattle Genetics, Inc. | P-amidobenzylethers in drug delivery agents |
| CA2462653C (en) * | 2001-11-07 | 2016-06-07 | Aya Jakobovits | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer |
| SI1545613T1 (sl) | 2002-07-31 | 2011-11-30 | Seattle Genetics Inc | Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni |
| US7498298B2 (en) | 2003-11-06 | 2009-03-03 | Seattle Genetics, Inc. | Monomethylvaline compounds capable of conjugation to ligands |
| WO2006132670A2 (en) | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the n terminus |
| JP5171621B2 (ja) | 2005-07-07 | 2013-03-27 | シアトル ジェネティックス， インコーポレイテッド | フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物 |
| US8871720B2 (en) | 2005-07-07 | 2014-10-28 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus |
| KR20140116546A (ko) | 2006-10-27 | 2014-10-02 | 제넨테크, 인크. | 항체 및 면역접합체 및 이들의 용도 |
| EP2265283B1 (en) | 2008-03-18 | 2014-09-03 | Seattle Genetics, Inc. | Auristatin drug linker conjugates |
| KR102023496B1 (ko) * | 2011-04-21 | 2019-09-20 | 시애틀 지네틱스, 인크. | 신규 결합제-약물 콘주게이트 (adc) 및 그의 용도 |
-
2011
- 2011-06-06 CN CN201180037305.4A patent/CN103200950B/zh active Active
- 2011-06-06 JP JP2013513651A patent/JP5791707B2/ja active Active
- 2011-06-06 ES ES11725412.8T patent/ES2528956T3/es active Active
- 2011-06-06 WO PCT/EP2011/059300 patent/WO2011154359A1/de not_active Ceased
- 2011-06-06 US US13/702,881 patent/US8722629B2/en active Active
- 2011-06-06 EP EP11725412.8A patent/EP2579887B1/de active Active
- 2011-06-06 CA CA2801971A patent/CA2801971C/en active Active